Revenue
2021
2022
2023
2024
Lipella Pharmaceuticals Inc. (LIPO)
Price—Loading quote
Financial statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue | $536,357 | $449,617 | $184,156 | $259,347 |
| Research & development | $3.6M | $3.0M | $2.5M | $1.5M |
| Operating expenses | $5.6M | $5.2M | $2.8M | $2.2M |
| Operating income | −$5.1M | −$4.7M | −$2.6M | −$1.9M |
| Operating margin | −947.23% | −1,055.55% | −1,406.26% | −738.71% |
| EBITDA | −$5.1M | −$4.7M | −$2.6M | −$1.9M |
| EBITDA margin | −946.69% | −1,055.18% | −1,406.26% | −738.71% |
| Net income | −$5.0M | −$4.6M | −$2.6M | −$1.9M |
| Net profit margin | −935.25% | −1,027.31% | −1,410.59% | −719.30% |
| Basic EPSper basic share | -$4.79 | -$6.16 | -$5.12 | -$4.40 |
| Diluted EPSper diluted share | -$4.79 | -$6.16 | -$5.12 | -$4.40 |
Owners
Reported shareholders